HSCI has begun Phase I-II clinical trials for the coronavirus vaccine Betuvax-CoV-2. The drug will be tested on 170 volunteers between the ages of 18 and 60. Participants will receive two components of the vaccine at 28-day intervals. The developers expect minimal side effects due to the characteristics of the composition. According to preclinical studies, the drug showed a good safety and efficacy profile with the formation of high titers of neutralizing antibodies.